Enrollment | Date of treatmenta | Observation period (months) | Endb | |||
---|---|---|---|---|---|---|
3 | 6 | 12 | ||||
Informed consent | ● | |||||
Eligibility screen | ● | |||||
Allocation | ● | |||||
Interventions | ||||||
6-mm diameter FCSEMS | ● | |||||
10-mm diameter FCSEMS | ● | |||||
Assessments | ||||||
Patient background | ● | |||||
Type of immediate bile duct drainage | ● | |||||
Presence and severity of acute cholangitis | ● | |||||
Peripheral blood count and biochemical tests | ● | |||||
Details of bile duct stenting procedure, prophylaxis use, and surgeon experience in ERCP | ● | |||||
Time to RBO | ● | |||||
Clinical success | ● | |||||
Blood tests | Every 3 months, until RBO occurs | |||||
Imaging studies | As needed | |||||
Non-RBO rate | ● | ● | ● | |||
Overall survival | ● | |||||
Presence of anti-tumor therapy | ● | |||||
Adverse events other than RBO | ● | |||||
Information on discontinuation | At any time |